How should ventricular tachycardia be evaluated and managed, including assessment of hemodynamic stability and appropriate pharmacologic and electrical interventions?

Approach to Ventricular Tachycardia

Immediate synchronized cardioversion is the definitive treatment for hemodynamically unstable ventricular tachycardia, while stable monomorphic VT should be treated with intravenous procainamide as first-line pharmacologic therapy. 1

Initial Assessment: Hemodynamic Stability

The critical first step is determining hemodynamic stability, which dictates the entire treatment pathway 1:

Hemodynamically unstable VT is defined by:

• Hypotension (systolic BP <90 mmHg) 1
• Pulmonary edema 1
• Ongoing chest pain/angina 1
• Altered mental status or loss of consciousness 2

Key principle: Wide-QRS tachycardia should be presumed to be VT if the diagnosis is unclear 1. This is a critical safety measure, as treating VT with agents appropriate for supraventricular tachycardia (particularly calcium channel blockers like verapamil or diltiazem) can cause hemodynamic collapse and ventricular fibrillation 1.

Management Algorithm

For Hemodynamically Unstable VT

Direct current cardioversion with appropriate sedation is mandatory 1:

• Monomorphic VT with rate >150 bpm: Start with 100 J synchronized shock 1
• Polymorphic VT (resembling VF): Use unsynchronized 200 J shock 1
• If initial shock fails, escalate to 200-300 J, then 360 J as needed 1

The evidence strongly supports electrical cardioversion as superior to pharmacologic therapy in unstable patients, avoiding drug-related complications while achieving immediate rhythm restoration 1.

For Hemodynamically Stable Monomorphic VT

Pharmacologic therapy is appropriate for stable patients (rate typically <150 bpm) 1:

First-line: Intravenous Procainamide 1, 3

• Dosing: 20-30 mg/min loading infusion up to 12-17 mg/kg (maximum 10 mg/kg at 50-100 mg/min over 10-20 minutes) 1, 3
• Maintenance: 1-4 mg/min infusion 1
• Class IIa recommendation from ACC/AHA guidelines 1
• Most efficacious agent for stable monomorphic VT, demonstrating superior conversion rates compared to lidocaine 1, 3
• Monitor blood pressure and QRS duration during infusion; stop if hypotension develops or QRS widens >50% 1
• Reduce infusion rate in renal dysfunction 1

Alternative agents when procainamide unavailable or contraindicated:

Amiodarone 1:

• Dosing: 150 mg IV over 10 minutes, followed by 1.0 mg/min for 6 hours, then 0.5 mg/min maintenance 1
• Class IIb recommendation for stable VT, but Class IIa for unstable VT refractory to cardioversion or recurrent despite other agents 1
• Preferred in patients with heart failure or acute myocardial infarction 1, 3
• Less effective for immediate conversion but useful for preventing recurrence 1

Lidocaine 1:

• Dosing: 1.0-1.5 mg/kg bolus, supplemental boluses of 0.5-0.75 mg/kg every 5-10 minutes to maximum 3 mg/kg total 1
• Maintenance: 2-4 mg/min (30-50 µg/kg/min) 1
• Class IIb recommendation specifically for VT associated with acute myocardial ischemia/infarction 1
• Reduce infusion rates in elderly patients and those with CHF or hepatic dysfunction to avoid toxicity 1
• Only moderately effective compared to procainamide 1, 3

For Polymorphic VT

Management depends on QT interval and underlying etiology 1:

Polymorphic VT with normal QT (ischemia-related):

• Immediate cardioversion if hemodynamically unstable 1
• Intravenous beta-blockers are first-line for recurrent episodes, especially if ischemia suspected 1
• Intravenous amiodarone for recurrent polymorphic VT in absence of prolonged QT 1
• Urgent angiography with revascularization for ischemic substrate 1

Torsades de pointes (prolonged QT):

• Intravenous magnesium (8 mmol bolus followed by 2.5 mmol/h infusion) even if serum magnesium normal 1
• Correct electrolyte abnormalities (potassium, magnesium) 1
• Discontinue QT-prolonging medications 1
• Consider overdrive pacing or isoproterenol to increase heart rate 1

Critical Contraindications

Never administer calcium channel blockers (verapamil, diltiazem) for wide-QRS tachycardia of unknown origin 1. This is a Class III recommendation (potentially harmful), particularly in patients with myocardial dysfunction, as these agents can precipitate hemodynamic collapse and ventricular fibrillation 1.

Post-Conversion Management

After successful cardioversion (electrical or pharmacologic):

• Anticipate atrial or ventricular premature complexes that may reinitiate tachycardia 1
• Consider antiarrhythmic infusion to prevent recurrence 1
• Infusions should typically be discontinued after 6-24 hours with reassessment of need for ongoing therapy 1
• Correct underlying electrolyte abnormalities (hypokalemia, hypomagnesemia) 1
• Address ischemia if present 1

Special Considerations

Refractory or recurrent VT:

• Transvenous catheter pace termination for VT refractory to cardioversion or frequently recurrent despite medications 1
• Consider urgent catheter ablation for incessant VT 1
• Aggressive ischemia reduction including intra-aortic balloon pump or emergency revascularization for ischemia-driven polymorphic VT 1

VT in specific contexts:

• Beta-blockers and sympathetic blockade are particularly effective for recurrent/refractory ventricular arrhythmias during electrical storm 1
• Structural heart disease VT requires different approach than idiopathic VT 4

Common Pitfalls

• Misdiagnosing VT as SVT with aberrancy: Always assume wide-complex tachycardia is VT unless proven otherwise 1
• Using adenosine indiscriminately: While adenosine may be relatively safe for undifferentiated regular wide-complex tachycardia, it can precipitate atrial fibrillation with rapid ventricular response in pre-excited states 1
• Delaying cardioversion in unstable patients: Electrical therapy should not be delayed for medication trials when hemodynamic compromise exists 1
• Inadequate monitoring during procainamide infusion: Blood pressure and ECG must be continuously monitored 1